Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Janine A. Clayton is active.

Publication


Featured researches published by Janine A. Clayton.


Menopause | 2014

The North American Menopause Society recommendations for clinical care of midlife women

Jan L. Shifren; Margery Gass; Risa Kagan; Andrew M. Kaunitz; James H. Liu; JoAnn V. Pinkerton; Peter F. Schnatz; Cynthia A. Stuenkel; Sherihan H. Allam; Rebecca H. Allen; Gloria Bachmann; C. Noel Bairey Merz; Wilma F. Bergfeld; Joel A. Block; Thomas B. Clarkson; Janine A. Clayton; Carrie Cwiak; Susan R. Davis; Dima L. Diab; Robert R. Freedman; George I. Gorodeski; Victor W. Henderson; Catherine A. Henry; Andrew G. Herzog; David Hutchins; Michelle Inkster; Hadine Joffe; Fredi Kronenberg; Tieraona Low Dog; JoAnn E. Manson

In celebration of the 25th anniversary of The North American Menopause Society (NAMS), the Society has compiled a set of key points and clinical recommendations for the care of midlife women. NAMS has always been a premier source of information about menopause for both healthcare providers and midli


The FASEB Journal | 2016

Studying both sexes: a guiding principle for biomedicine.

Janine A. Clayton

In May 2014, the U.S. National Institutes of Health (NIH) announced that it will ensure that investigators account for sex as a biological variable (SABV) in NIH‐funded preclinical research as part of the agencys rigor and transparency initiative. Herein, I describe in more detail the rationale behind the SABV policy component and provide additional detail about policy goals. In short, studying both sexes is a guiding principle in biomedical research that will expand knowledge toward turning discovery into health. NIH expects that considering SABV in preclinical research will help to build a knowledge base that better informs the design of clinical research and trials in humans. Integrating the practice of studying both sexes in preclinical research will, over time, expand our currently incomplete knowledge base that plays a critical role in informing the development of sex‐and gender‐appropriate medical care for women and men.—Clayton, J. A. Studying both sexes: a guiding principle for biomedicine. FASEB J. 30, 519‐524 (2016). www.fasebj.org


Scientific Reports | 2013

International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I)

Yoko Ogawa; Stella K. Kim; Reza Dana; Janine A. Clayton; Sandeep Jain; Mark I. Rosenblatt; Victor L. Perez; Hasanain Shikari; Anjo Riemens; Kazuo Tsubota

The International Chronic Ocular GVHD Consensus Group held 4 working meetings to define new diagnostic metrics for chronic ocular graft-versus-host disease (GVHD). After considering the factors currently used to diagnose chronic ocular GVHD, the Consensus Group identified 4 subjective and objective variables to measure in patients following allogeneic hematopoietic stem cell transplantation (HSCT): OSDI, Schirmers score without anesthesia, corneal staining, and conjunctival injection. Each variable was scored 0–2 or 0–3, with a maximum composite score of 11. Consideration was also given to the presence or the absence of systemic GVHD. On the basis of their composite score and the presence or absence of systemic GVHD, patients were assigned to one of three diagnostic categories: NO, PROBABLE, or DEFINITE ocular GVHD. New diagnostic criteria for chronic ocular GVHD are presented by the Consensus Group. Validation studies are needed to identify the best combination of the proposed metrics to maximize diagnostic sensitivity and specificity.


JAMA | 2016

Reporting Sex, Gender, or Both in Clinical Research?

Janine A. Clayton; Cara Tannenbaum

Virtually every clinical research report includes basic demographic characteristics about the study participants, such as age, and how many participants were male/men or female/women. Some research articles refer to this latter variable as sex, others refer to it as gender. As one of the first pieces of data reported, the importance of including sex appears undisputed. But what does the sex-gender category really entail, and how should it be reported? With emerging evidence that both sex and gender have an effect, for instance, on how an individual selects, responds to, metabolizes, and adheres to a particular drug regimen,1 there is an ethical and scientific imperative to report to whom research results apply. This Viewpoint explains the contexts in which sex and gender are relevant and provides suggestions for improving reporting of this characteristic.


Biology of Sex Differences | 2016

Evaluating sex as a biological variable in preclinical research: the devil in the details.

Cara Tannenbaum; Jaclyn M. Schwarz; Janine A. Clayton; Geert J. De Vries; Casey Sullivan

Translating policy into action is a complex task, with much debate surrounding the process whereby US and Canadian health funding agencies intend to integrate sex and gender science as an integral component of methodological rigor and reporting in health research. Effective January 25, 2016, the US National Institutes of Health implemented a policy that expects scientists to account for the possible role of sex as a biological variable (SABV) in vertebrate animal and human studies. Applicants for NIH-funded research and career development awards will be asked to explain how they plan to factor consideration of SABV into their research design, analysis, and reporting; strong justification will be required for proposing single-sex studies. The Canadian Institutes of Health Research is revising their peer review accreditation process to ensure that peer reviewers are skilled in applying a critical lens to protocols that should be incorporating sex and gender science. The current paper outlines the components that peer reviewers in North America will be asked to assess when considering whether SABV is appropriately integrated into research designs, analyses, and reporting. Consensus argues against narrowly defining rules of engagement in applying SABV, with criteria provided for reviewers as guidance only. Scores will not be given for each criterion; applications will be judged on the overall merit of scientific innovation, rigor, reproducibility, and potential impact.


Ophthalmology | 2013

Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage.

Brian P. Brooks; Amy H. Thompson; Rachel J. Bishop; Janine A. Clayton; Chi-Chao Chan; Ekaterini Tsilou; Wadih M. Zein; Deborah Tamura; Sikandar G. Khan; Takahiro Ueda; Jennifer Boyle; Kyu Seon Oh; Kyoko Imoto; Hiroki Inui; Shinichi Moriwaki; Steffen Emmert; Nicholas T. Iliff; Porcia T. Bradford; John J. DiGiovanna; Kenneth H. Kraemer

OBJECTIVE Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by mutations in DNA repair genes. Clinical manifestations of XP include mild to extreme sensitivity to ultraviolet radiation resulting in inflammation and neoplasia in sun-exposed areas of the skin, mucous membranes, and ocular surfaces. This report describes the ocular manifestations of XP in patients systematically evaluated in the Clinical Center at the National Institutes of Health. DESIGN Retrospective observational case series. PARTICIPANTS Eighty-seven participants, aged 1.3 to 63.4 years, referred to the National Eye Institute (NEI) for examination from 1964 to 2011. Eighty-three patients had XP, 3 patients had XP/Cockayne syndrome complex, and 1 patient had XP/trichothiodystrophy complex. METHODS Complete age- and developmental stage-appropriate ophthalmic examination. MAIN OUTCOME MEASURES Visual acuity; eyelid, ocular surface, and lens pathology; tear film and tear production measures; and cytologic analysis of conjunctival surface swabs. RESULTS Of the 87 patients, 91% had at least 1 ocular abnormality. The most common abnormalities were conjunctivitis (51%), corneal neovascularization (44%), dry eye (38%), corneal scarring (26%), ectropion (25%), blepharitis (23%), conjunctival melanosis (20%), and cataracts (14%). Thirteen percent of patients had some degree of visual axis impingement, and 5% of patients had no light perception in 1 or both eyes. Ocular surface cancer or a history of ocular surface cancer was present in 10% of patients. Patients with an acute sunburning skin phenotype were less likely to develop conjunctival melanosis and ectropion but more likely to develop neoplastic ocular surface lesions than nonburning patients. Some patients also showed signs of limbal stem cell deficiency. CONCLUSIONS Our longitudinal study reports the ocular status of the largest group of patients with XP systematically examined at 1 facility over an extended period of time. Structural eyelid abnormalities, neoplasms of the ocular surface and eyelids, tear film and tear production abnormalities, ocular surface disease and inflammation, and corneal abnormalities were present in this population. Burning and nonburning patients with XP exhibit different rates of important ophthalmologic findings, including neoplasia. In addition, ophthalmic characteristics can help refine diagnoses in the case of XP complex phenotypes. DNA repair plays a major role in protection of the eye from sunlight-induced damage.


Journal of Womens Health | 2011

Clinical Research Enrolling Pregnant Women: A Workshop Summary

Mary A. Foulkes; Christine Grady; Catherine Y. Spong; Angela Bates; Janine A. Clayton

Clinical research investigates mechanisms of human disease, interventions, or new technologies, but pregnant women are often excluded from clinical studies. Few studies, beyond research on pregnancy, are designed to address questions relevant to pregnant women. A recent National Institutes of Health workshop considered the barriers and opportunities in conducting clinical research studies enrolling pregnant women.


Ophthalmology | 2010

Evaluation of the Age-Related Eye Disease Study Clinical Lens Grading System: AREDS Report No. 31

Emily Y. Chew; Jonghyeon Kim; Robert D. Sperduto; Manuel B. Datiles; Hanna R. Coleman; Darby J. S. Thompson; Roy C. Milton; Janine A. Clayton; Larry D. Hubbard; Ronald P. Danis; Frederick L. Ferris

PURPOSE To examine the grading (interrater) reliability of the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System (ARLNS). DESIGN Evaluation of diagnostic test or technology. PARTICIPANTS One hundred fifty volunteers (284 eyes). METHODS Participants with lens opacities of varying severity were independently graded at the slit lamp for cataract severity by 2 examiners (retinal or anterior segment specialists) using the ARLNS, which employs 3 standard photographs of increasing severity for classifying each of the 3 major types of opacity. Lens photographs were taken and graded at a reading center using the more detailed AREDS System for Classifying Cataracts from photographs. MAIN OUTCOME MEASURES The Pearson correlation, weighted-kappa, and limits-of-agreement statistics were used to assess the interrater agreement of the gradings. RESULTS Examinations were performed on 284 lenses (150 participants). Tests of interrater reliability between pairs of clinicians showed substantial agreement between clinicians for cortical and posterior subcapsular opacities and moderate agreement for nuclear opacities. A similar pattern and strength of agreement was present when comparing scores of retinal versus anterior segment specialists. Interrater agreement between clinical and reading center gradings was not as great as inter-clinician agreement. CONCLUSIONS Interrater agreements were in the moderate to substantial range for the clinical assessment of lens opacities. Inherent differences in cataract classification systems that rely on slit lamp vs photographic assessments of lens opacities may explain some of the disagreement noted between slit lamp and photographic gradings. Given the interrater reliability statistics for clinicians and the simplicity of the grading procedure, ARLNS is presented for use in studies requiring a simple, inexpensive method for detecting the presence and severity of the major types of lens opacities. FINANCIAL DISCLOSURE(S) The authors have no proprietary or commercial interest in any of the materials discussed in this article.


Seminars in Reproductive Medicine | 2013

Racial and ethnic health disparities in reproductive medicine: an evidence-based overview.

Carter Owen; Ellen H. Goldstein; Janine A. Clayton; James H. Segars

Racial and ethnic health disparities in reproductive medicine exist across the life span and are costly and burdensome to our healthcare system. Reduction and ultimate elimination of health disparities is a priority of the National Institutes of Health who requires reporting of race and ethnicity for all clinical research it supports. Given the increasing rates of admixture in our population, the definition and subsequent genetic significance of self-reported race and ethnicity used in health disparity research is not straightforward. Some groups have advocated using self-reported ancestry or carefully selected single-nucleotide polymorphisms, also known as ancestry informative markers, to sort individuals into populations. Despite the limitations in our current definitions of race and ethnicity in research, there are several clear examples of health inequalities in reproductive medicine extending from puberty and infertility to obstetric outcomes. We acknowledge that socioeconomic status, education, insurance status, and overall access to care likely contribute to the differences, but these factors do not fully explain the disparities. Epigenetics may provide the biologic link between these environmental factors and the transgenerational disparities that are observed. We propose an integrated view of health disparities across the life span and generations focusing on the metabolic aspects of fetal programming and the effects of environmental exposures. Interventions aimed at improving nutrition and minimizing adverse environmental exposures may act synergistically to reverse the effects of these epigenetic marks and improve the outcome of our future generations.


Science | 2016

Basic science: Bedrock of progress

Francis S. Collins; James M. Anderson; Christopher P. Austin; James F. Battey; Linda S. Birnbaum; Josephine P. Briggs; Janine A. Clayton; Bruce N. Cuthbert; Robert W. Eisinger; Anthony S. Fauci; John I. Gallin; Gary H. Gibbons; Roger I. Glass; Michael M. Gottesman; Patricia A. Gray; Eric D. Green; Franziska B. Greider; Richard J. Hodes; Kathy Hudson; Betsy L. Humphreys; Stephen I. Katz; George F. Koob; Walter J. Koroshetz; Michael S. Lauer; Jon R. Lorsch; Douglas R. Lowy; John J. McGowan; David Murray; Richard Nakamura; Andrea Norris

Almost 4 years ago, one of us (F.S.C.) wrote an Editorial ([ 1 ][1]) affirming the continued importance of basic research to the National Institutes of Health (NIH) mission. The Editorial emphasized that basic scientific discovery is the engine that powers the biomedical enterprise, and NIH

Collaboration


Dive into the Janine A. Clayton's collaboration.

Top Co-Authors

Avatar

Claudette E. Brooks

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Susan Vitale

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Terri L. Cornelison

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Frederick L. Ferris

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Leah R. Miller

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Lisa Begg

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Manuel B. Datiles

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Michael S. Lauer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge